Ranbaxy Receives Approval To Manufacture And Market Hydrocodone Bitartrate And Acetaminophen Tablets USP

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Hydrocodone Bitartrate and Acetaminophen Tablets USP, 7.5 mg/750 mg, 10 mg/500 mg, 5 mg/500 mg, and 10 mg/325 mg strengths. The Office of Generic Drugs, U.S. [click link for full article]

More: continued here

Filed under: Pain / Anesthetics on August 22nd, 2007